LEGEND BIOTECH CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 45.57 USD | -2.13% |
|
+13.90% | -24.26% |
Financials (USD)
| Sales 2024 * | 528M | Sales 2025 * | 1.02B | Capitalization | 8.31B |
|---|---|---|---|---|---|
| Net income 2024 * | -341M | Net income 2025 * | -167M | EV / Sales 2024 * | 14.3 x |
| Net cash position 2024 * | 743M | Net cash position 2025 * | 845M | EV / Sales 2025 * | 7.3 x |
| P/E ratio 2024 * |
-43.7
x | P/E ratio 2025 * |
-81.9
x | Employees | 2,000 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.8% |
More Fundamentals
* Assessed data
More news
Latest transcript on Legend Biotech Corporation
More recommendations
More press releases
More news
| 1 day | -2.13% | ||
| 1 week | +13.90% | ||
| Current month | +13.90% | ||
| 1 month | +0.11% | ||
| 3 months | -27.95% | ||
| 6 months | -23.13% | ||
| Current year | -24.26% |
1 week
39.74
46.94
1 month
38.6046.94
Current year
38.6070.13
1 year
38.6077.32
3 years
30.7677.32
5 years
23.4177.32
10 years
23.4177.32
| Managers | Title | Age | Since |
|---|---|---|---|
Ying Huang
CEO | Chief Executive Officer | 51 | 19-06-30 |
Lori Macomber
DFI | Director of Finance/CFO | 53 | 19-08-31 |
Tracy Luo
CTO | Chief Tech/Sci/R&D Officer | - | 18-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ying Huang
CEO | Chief Executive Officer | 51 | 19-06-30 |
Corazon Sanders
BRD | Director/Board Member | 67 | 20-04-30 |
Li Zhu
BRD | Director/Board Member | 74 | 20-11-22 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.08% | 4 M€ | -27.92% | ||
| 1.18% | 2 M€ | -14.14% | ||
| 0.99% | 1 M€ | -18.21% | - | |
| 0.95% | 11 M€ | -6.03% | - | |
| 0.58% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-07 | 45.57 | -2.13% | 965,307 |
| 24-06-06 | 46.56 | +6.69% | 2,232,906 |
| 24-06-05 | 43.64 | +5.56% | 1,564,395 |
| 24-06-04 | 41.34 | +3.27% | 2,122,113 |
| 24-06-03 | 40.03 | +0.05% | 3,010,313 |
Delayed Quote Nasdaq, June 07, 2024 at 04:00 pm EDT
More quotes
Legend Biotech Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
45.57
USD
Average target price
82.53
USD
Spread / Average Target
+81.11%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -24.26% | 8.31B | |
| +18.72% | 125B | |
| +14.19% | 108B | |
| -4.93% | 24.21B | |
| +1.05% | 22.78B | |
| -11.23% | 17.96B | |
| -41.74% | 16.43B | |
| -13.31% | 16.37B | |
| +2.44% | 13.58B | |
| +27.89% | 11.66B |
- Stock Market
- Equities
- LEGN Stock
